IDH1 and astrocytoma (excluding glioblastoma): One recent report identified IDH mutation in Grades 2 and 3 astrocytomas as an indicator of better clinical outcome–addressing a pertinent challenge, as these lower-grade astrocytomas can have widely variable outcomes [9].